{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-22-000079","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2022-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.112678+00:00","generated_at":"2026-06-24T06:04:02.468718+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nautilus Q2 net loss $14.7M; cash $334.9M; platform launch on track for mid-2024","bullets":["Operating expenses of $15.5M in Q2 2022, down from $16.0M in Q1 2022.","Net loss of $14.7M for Q2 2022 vs. $10.7M in Q2 2021; cash, equivalents & investments $334.9M.","Platform launch (instruments and reagents) targeted for mid-2024; early access revenue starting early 2024.","Anticipates cash runway extending well into 2025.","Hired Eric Spence (VP Instrument Engineering) and Ken Kuhn (VP Reagent & Process Development)."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-22-000079","json":"https://secwatch.observer/filing/0001808805-22-000079.json","markdown":"https://secwatch.observer/filing/0001808805-22-000079.md","text":"https://secwatch.observer/filing/0001808805-22-000079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000079/0001808805-22-000079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000079/naut-20220802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:04:02.468718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}